A B S T R A C T Hepatic and renal extraction of immunoreactive parathyroid hormone (i-PTH) was studied in awake dogs with explanted kidneys and chronic indwelling hepatic vein catheters. After a single injection of bovine PTH 1-84 (b-PTH 1-84), hepatic arteriovenous (A-V) differences for immunoreactive PTH (i-PTH) was 39% at 2 min after injection but decreased to 0% by 25 min, despite high levels of i-PTH in the arterial circulation. Gel filtration of arterial and hepatic venous samples obtained when hepatic A-V differences for i-PTH were demonstrable revealed hepatic uptake of the intact hormone and addition of a smaller COOH-terminal fragment, eluting just after the intact hormone, to the hepatic venous blood. Gel filtration of samples obtained 20-30 min after injection of b-PTH 1-84 (when no hepatic A-V difference for i-PTH was demonstrable) revealed no detectable intact hormone in the circulation. Levels of COOH-terminal fragments of the hormone at the time were identical in arterial and hepatic venous samples. In additional experiments no hepatic A-V difference was observed after the injection of the synthetic bovine PTH 1-34 (syn b-PTH 1-34). By comparison there was a demonstrable A-V difference of 20% across the kidney for both intact PTH and COOH-terminal fragments that persisted until i-PTH disappeared from the circulation. The kidney also demonstrated an A-V difference of 22% after injection of syn b-PTH 1-34. These studies demonstrate selective extraction of intact PTH but not of its fragments by the liver. The kidney, on the other hand, extracted the intact hormone and both COOH and NHs terminal frag-
INTRODUCTION
Immunoreactive circulating parathyroid hormone (PTH)1 exists as a heterogenous mixture of the intact hormone and its fragments (1) (2) (3) (4) . There is some controversy as to whether the parathyroid glands secrete exclusively the intact 84-amino acid polypeptide (5) or whether they also secrete some of the fragments found in the circulation (4, 6) . The major target organs of PTH are kidney (7) and bone (8) , with other possible sites of action in the liver (9) and the intestine (10) .
To date, the kidney and the liver have been shown to be able to degrade the hormone ( 11, 12) .
Previous studies from this laboratory demonstrated a 20% extraction of delivered carboxyl (COOH) terminal PTH imiimunoreactivity by the kidney of awake dogs (13) . This arteriovenous (A-V) difference of 20% was maintained as the circulating form of the hormone changed from the intact species predominately to COOH-terminal fragments. Isolated perfused dog kidneys in vitro demonstrated uptake and progressive degradation of intact bovine (b)-PTH (14) with the production and subsequent metabolism of smaller molecular weight fragments from both the COOH and amino (NH2) terminal portions of the molecule.
The dog studies in vivo (13) also demonstrated that extrarenal sites of metabolism accounted for approximately 40% of the removal of COOH-terminal immunoreactivity from the circulation after the injection of b-PTH 1-84. Also, approximately 60% of the removal 'Abbreviations u(sed in this paper: A-V, arteriovenous;
ICG, indocyanine green; b-PTH, bovine parathyroid hormone; i-PTH, immunoreactive parathyroid hormone; syn-PTH, synthetic parathyroid hormone.
rate of NH2-terminal immunoreactivity was accounted for by extrarenal sites when bovine synthetic PTH 1-34 (syn b-PTH 1-34) was injected.
The liver is apparently a major extrarenal site for the degradation of PTH. A prolonged disappearance time of injected radiolabeled 'I-PTH has been demonstrated in partially hepatectomized rats (15) . Studies in vitro have demonstrated progressive degradation of the intact hormone and release of hormonal fragments into the perfusion medium by the isolated perfused rat liver (12) . The fragments produced included a large COOH-terminal fragment wiith an estimated mol wt of 7,000 that appeared to be secondarily degraded to a COOH-terminal fragment, approximate mol wt 3,500. Also, an NH2-terminal fragment, approximate mol wt 3,500, was detected in the perfusate.
The present studies were undertaken to examine further the role of the liver in the metabolism of PTH in vivo. They demonstrate selective uptake of b-PTH 1-84 by the liver and the absence of detectable hepatic uptake of smaller COGH-terminal fragments or of injected syn b-PTH 1-34. Concomitant studies in the kidney demonstrated uptake of the intact hormone and its fragments.
METHODS
Preparationt of dogs. Studies were performed on female mongrel dogs weighing 12-32 kg. Dogs were fed standard Purina dog chow (Ralston Purina Co., St. Louis, Mo.) and had free access to water. Before study, a catheter was placed in a hepatic vein by a modification of the procedure described by Shoemaker et al. (16) . Through a midline abdominal incision, the left common hepatic vein was identified. A guide wire was introduced through a 16-gauge needle, over which a polyethylene catheter was advanced 1-2 cm into the vein and sutured in place. The catheter was brought out through a stab wound in the right flank and filled with heparin. Initial studies were performed 4-10 days after surgery. Patency of the catheter was maintained for 8-10 wk by filling the catheter with heparin every 5-7 days.
In addition to the hepatic vein catheter, another group of dogs had the left kidney explanted to a subcutaneous position, as previously described (13 (13) . Iodinated peptides were added to the assay tubes after 3-4 days of initial incubation. After 1-2 days of additional incubation, total counts added were determined; after separation of free from bound counts by charcoal-coated dextran as previously described (13) Endogenous canine i-PTH assayed in the above system (b-PTH 1-84 standard) was subtracted as a background from all samples (normal range 0.1-0.45 ng b-PTH eq/ml).
Gel filtration. Arterial and hepatic venous plasma samples (1.5 ml) were filtered on 50-90 X 1.5-cm columns of BioGel P-10 (Bio-Rad Laboratories, Richmond, Calif.), calibrated by the elution position of dextran blue, 'I-b-PTH 1-84, 'I-insulin, and 'I-syn b-PTH 1-34. The column eluant was 0.15 M ammonium acetate with 2.5 mg/ml bovine serum albumin, pH 5.5. Column flow rate was 5-10 ml/h, and 0.5-ml fractions were collected.
i-PTH in the column eluates was determined in two radioimmunoassays, one using antiserum CH9 preincubated with excess syn b-PTH 1-34 (10 ng/tube at 4°C for 24 h with constant agitation) to render it COOH-terminal-specific and the other using CH9N, an NH2-terminal-specific antiserum as previously described (13) . To correct for any effect of column buffer on the binding between PTH and the antisera, appropriate controls for nonspecific binding, tracer binding, and standard curves were performed with volumes of column eluant equal to the test sample volumes. The pH of this assay mixture was 8.2 as compared to a pH of 8.6 for standard assay mixtures. The effect of this addition of column buffer on the radioimmunoassays was insignificant.
Calctulations. Hepatic plasma flow was calculated by dividing the infusion rate of ICG (in micrograms per minute) by the hepatic A-V difference. Renal plasma flow was calculated by the Wolff modification of the Fick principle (22) . The percent hepatic and renal extraction of i-PTH was determined by dividing the A-V difference by the arterial i-PTH concentration.
RESULTS
Adequacy of hepatic vein samizpling. (Fig. 1) . This occurred despite a lack of change in hepatic blood flow as measured by extraction of ICG and despite persisting high levels of immunoreactive PTH in the circulation that did not return to base-line values until 150-180 min after injection. In five additional dogs in which renal extraction was determined simultaneously with hepatic extraction (Fig. 2) , the pattern of hepatic extraction was similar to that seen in Fig. 1 . However, renal extraction of i-PTH wvas constant at 20+0.68% and remained stable until i-PTH disappeared from the circulation.
The possibility that the cessation of extraction of PTH by the liver might represent a saturation phenome- ples in plasma pools obtained from three dogs 6 min after injection of b-PTH 1-84. Again the elution pattern of i-PTH in arterial plasma revealed a large peak eluting with the mI-b-PTH marker representing intact hormone, a smaller peak representing a COOH-terminal fragment (apparent mol wt 6,000-7,000) and a small amount of COOH-terminal immunoreactivity eluting with the syn b-PTH 1-34 marker (apparent mol wt 3,500). Again in hepatic venous plasma, the peak representing intact hormone was markedly reduced, and the amount of the COOH-terminal peak (apparent mol wt 7,000) was increased as compared to arterial samples. The elution patterns of NH2-terminal immunoreactivity (not illustrated) revealed peaks consistent with intact hormone and a smaller, late-eluting fragment appearing with the syn b-PTH 1-34 marker. Again, there was evidence for a large hepatic uptake of NH2-terminal immunoreactivity in the elution position of the intact hormone marker but not difference between the arterial and venous elution patterns for the late-eluting fragment. Fig. 6 shows the elution pattern of COOH-terminal immunoreactivity in arterial and hepatic venous plasma 20 min after injection of b-PTH 1-84 when no extraction was demonstrable by radioimmunoassay. At this time the intact hormone peak was no longer present, and the predominant peaks were a COOH-terminal fragment (apparent mol wt 7,000) in both artery and hepatic vein samples and also a smaller COOH-terminal peak (apparent mol wt. 3,500). There was no significant difference between the elution patterns from arterial and hepatic venous samples. Each point represents mean extraction± SE in three dogs.
When infusion was stopped, sampling was continued in one animal.
animals with explanted kidneys in addition to catheters in hepatic and portal veins. Thus, simultaneous extraction of i-PTH by the liver, kidney, and portal systems could be evaluated and compared in the same animals.
The results of these studies are shown in Fig. 8 . No aorto-portal venous difference of COOH-terminal i-PTH was observed, whereas both the liver and kidney demonstrated constant extraction of 24.1±0.2% and 20.0± 0.7%, respectively. In one animal in whom sampling was continued after the infusion was stopped, the difference between hepatic and renal extraction was apparent and similar to that shown in Fig. 2 . Thus, under conditions of constant delivery of intact b-PTH 1-84, the liver demonstrates constant extraction that rapidly disappears upon termination of the infusion. DISCUSSION Degradation of PTH has been demonstrated in studies in vitro using saline extracts of porcine liver (24) and the isolated perfused rat liver (12) . The latter studies demonstrated production of PTH fragments by the liver when it was perfused with either tritiated or unlabeled b-PTH 1-84. The fragments generated during liver perfusion were similar to those seen in the fractionation of human hyperparathyroid serum (2) . A previous study in vivo of the role of the liver in PTH metabolism documented slower disappearance of injected 'I-b-PTH after partial hepatectomy in the rat (15) .
In the present studies, a reliable means of repeatedly obtaining hepatic venous blood from awake, resting dogs was utilized, thus avoiding the possible effects of anesthetic agents on hepatic metabolism and PTH degradation. The decrease and disappearance of hepatic i-PTH A-V differences after a single injection of b-PTH 1-84 was reproducible under several different experimental conditions, including seven dogs in which only hepatic extraction was studied (Fig. 1) , five dogs with a left explanted kidney, in which simultaneous hepatic and renal venous samples were obtained (Fig.  2) , three dogs given two separate injections of b-PTH 1-84 (Fig. 3) , and one animal after cessation of constant infusion (Fig. 8) . The disappearance of the initial hepatic A-V difference for i-PTH by 15-25 min after injection apparently was not accounted for by a saturation phenomenon, since a reinjection of b-PTH 1-84 at 60 min (Fig. 3) or at 20 min (not shown), resulted in extraction of immunoreactivity by the liver again, in spite of persisting high levels of immunoreactivity remaining in the circulation after the initial inj ection.
Further investigation of the nature of the immunoreactivity in the circulation by gel filtration studies revealed that in the first several minutes after injection of b-PTH 1-84 when a hepatic A-V difference for i-PTH was detectable there was a large difference between arterial and venous samples in the size of the peak of immunoractivity eluting with the intact hormone marker. This suggests a hepatic uptake mechanism for intact PTH 1-84 with a large capacity, and indicates that the liver is probably one of the major sites of uptake of the intact hormone (PTH 1-84). The gel filtration studies of samples obtained less than 20 min after injection also document the release of a COOH-terminal fragment of i-PTH into the hepatic venous circulation. This fragment elutes just after the intact hormone marker, similar to the previously described COOH-terminal fragment that makes up the greater portion of circulating i-PTH (2), and is thought to represent the initial cleavage product of intact hormone (25) an explanted kidney given a single injection of the synthetic NH2-terminal fragment, syn b-PTH 1-34. In these studies, as was reported previously (11) , this peptide was rapidly cleared from the circulation. The renal extraction of 22% was stable throughout its disappearance from the circulation, and renal clearance accounted for approximately 40% of the total disappearance rate of NH2-terminal i-PTH. Absence of hepatic uptake of NH.-terminal i-PTH was a surprising finding that probably cannot be accounted for by differences between the synthetic bovine and the native canine NHa-terminal tetratricontapeptide, since there was a rapid uptake of the bovine synthetic peptide by the kidney and other unknown sites. Studies done with portal vein catheters in place indicate that neither the intestine or the spleen account for the extrarenal metabolism of syn b-PTH 1-34. Nor do these organs demonstrate detectable uptake of COOH-terminal immunoreactivity after b-PTH 1-84 injections.
The above patterns of hepatic PTH uptake contrast markedly with those by the kidney reported here and in previous studies (13) . The kidney demonstrated uptake of COOH-terminal immunoreactivity with an A-V difference of 20% early after injection of PTH 1-84 when intact hormone is the major circulating species and at later times when the intact hormone had disappeared from the circulation and largely COOH-terminal fragments remained. The kidney also avidly extracts injected syn b-PTH 1-34.
The data thus far suggest a selective uptake of intact PTH by the liver. If this is so, then one would expect to find continued and constant extraction of i-PTH by the liver under conditions of constant delivery of intact PTH. The studies in Fig. 8 during constant infusion of b-PTH 1-84 confirm this interpretation and provide additional data to exclude the possibility that hepatic extraction was only occurring at the high plasma levels of immunoreactivity seen after single injection. The plasma levels during constant infusion (1.6±0.2 ng/ml) of b-PTH 1-84 are considerably lower than the level of i-PTH in the plasma when hepatic extraction ceases after single injection.
The physiological role of the differences between hepatic and renal uptake of i-PTH in the overall metabolism of the hormone cannot be ascertained from the type of experiments reported in the present studies. The renal uptake of the COOH-terminal fragments of PTH, shown to be biologically inactive (26) , and the failure to demonstrate hepatic uptake of these fragments, suggest that the kidney may have an uptake mechanism linked to degradation of these peptides. Uptake of COOH-terminal fragments may be separable from uptake linked to the biological effects of PTH. Conversely, the liver appears to possess a mechanism specific for the uptake of the intact hormone and to have no role in the catabolism of PTH fragments. Uptake of PTH fragments limited to the kidney could explain the marked accumulation and predominance of COOH-terminal fragments seen in the circulation of patients with chronic renal failure.
